Stratification of lung squamous cell carcinoma based on ferroptosis regulators: Potential for new therapeutic strategies involving ferroptosis induction. (March 2022)

• Record Type: Journal Article
• Authors: Asakawa, Ayaka; Kawade, Genji; Kurata, Morito; Fukuda, Sho; Onishi, Iichiroh; Kinowaki, Yuko; Ishibashi, Sachiko; Ikeda, Masumi; Watabe, Shiori; Kobayashi, Masashi; Ishibashi, Hironori; Okubo, Kenichi; Kitagawa, Masanobu; Yamamoto, Kouhei
• Is Part Of: Lung cancer. Volume 165(2022)
• Page Start: 82
• Page End: 90
• Publication Date: 2022-03
• Subjects: Lung squamous cell carcinoma -- Lipid peroxidation -- Nonapoptotic cell death -- Ferroptosis -- Therapy -- Refractive cancer; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2022.01.012
• Languages: English
• ISSNs: 0169-5002

Abstract

Abstract: Objectives: Lung squamous cell carcinoma (LSCC) exhibits poor response to treatment compared with other lung cancer subtypes, resulting in worse prognosis. Therefore, new therapeutic strategies are required for advanced LSCC. Ferroptosis is a recently discovered nonapoptotic cell death caused by intracellular lipid peroxidation that can bring about effective cell death in cancer cells resistant to apoptosis. Hence, ferroptosis is a potential therapeutic strategy for refractory cancer. Materials and Methods: In this study, we performed clinicopathological and molecular analyses on tumor specimens from 270 patients with squamous cell lung cancer, focusing on the expression of glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1), which are known to be key regulators of ferroptosis, and the accumulation of 4-hydroxynoneral (4-HNE), a lipid peroxidation marker. Results: Immunohistochemistry revealed that patients with low 4-HNE accumulation and low levels of GPX4 or FSP1 had significantly worse prognoses than other patients (P = 0.001). This stratification was an independent prognostic predictor (P = 0.003). A dramatic cell death synergistic effect was observed on LSCC-derived LK-2 and EBC1 cells treated with GPX4 and FSP1 inhibitors. This effect was completely inhibited by treatment with the ferroptosis inhibitor. Notably, this was not the case in LK-2 cells treated with the apoptosis inhibitor, and in these cells, ferroptosis was induced. Conclusion: Ferroptosis regulators GPX4 and FSP1 are associated with lung squamous cell cancer cancer's prognosis. We present the clinicopathological and molecular basis of novel therapeutic strategies for refractory LSCC.